Construction and experimental validation of a signature for predicting prognosis and immune infiltration analysis of glioma based on disulfidptosis-related lncRNAs
Frontiers in Immunology · 2023
DOI: 10.3389/fimmu.2023.1291385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Youwei Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Glioma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Backgrounds Disulfidptosis, a newly discovered mechanism of programmed cell death, is believed to have a unique role in elucidating cancer progression and guiding cancer therapy strategies. However, no studies have yet explored this mechanism in glioma.
Methods
We downloaded data on glioma patients from online databases to address this gap. Subsequently, we identified disulfidptosis-related genes from published literature and verified the associated lncRNAs.
Results
Through univariate, multivariate, and least absolute shrinkage and selection operator (LASSO) regression algorithms analyses, we identified 10 lncRNAs. These were then utilized to construct prognostic prediction models, culminating in a risk-scoring signature. Reliability and validity tests demonstrated that the model effectively discerns glioma patients’ prognosis outcomes. We also analyzed the relationship between the risk score and immune characteristics, and identified several drugs that may be effective for high-risk patients. In vitro experiments revealed that LINC02525 could enhances glioma cells’ migration and invasion capacities. Additionally, knocking down LINC02525 was observed to promote glioma cell disulfidptosis.
Conclusion
This study delves into disulfidptosis-related lncRNAs in glioma, offering novel insights into glioma therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Neurosurgery, the First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Cancer Research Institute, Department of Neurosurgery, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Health Commission (NHC) Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medical Science, Central South Univers…
Zitieren
APA
Guo, Y., Jiang, Z., Chen, Q., Xie, D., Zhou, Y., Yin, W., Wang, Z., Wang, B., Ren, C., & Jiang, X. (2023). Construction and experimental validation of a signature for predicting prognosis and immune infiltration analysis of glioma based on disulfidptosis-related lncRNAs. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1291385
Vancouver
Guo Y, Jiang Z, Chen Q, Xie D, Zhou Y, Yin W, et al. Construction and experimental validation of a signature for predicting prognosis and immune infiltration analysis of glioma based on disulfidptosis-related lncRNAs. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2023.1291385
BibTeX
@article{Guo2023,
author = {Guo, Youwei and Jiang, Zhipeng and Chen, Quan and Xie, Dongcheng and Zhou, Yi and Yin, Wen and Wang, Zihan and Wang, Binbin and Ren, Caiping and Jiang, Xingjun},
title = {Construction and experimental validation of a signature for predicting prognosis and immune infiltration analysis of glioma based on disulfidptosis-related lncRNAs},
journal = {Frontiers in Immunology},
year = {2023},
doi = {10.3389/fimmu.2023.1291385}
}
EUVIMED